Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?

OBJECTIVES:. To examine whether interleukin-6 in critical coronavirus disease 2019 is higher in arterial than in central venous blood, as a sign of predominantly local pulmonal rather than systemic interleukin-6 production. DESIGN:. Prospective cohort pilot study with repeated weekly measurements of...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Nikolai Ravn Aarskog, MD, Hans Christian Aass, PhD, Jan Cato Holter, MD, PhD, Morten Rostrup, MD, PhD, Aleksander Rygh Holten, MD, PhD
Format:	article
Langue:	EN
Publié:	Wolters Kluwer 2021
Sujets:	Medical emergencies. Critical care. Intensive care. First aid RC86-88.9
Accès en ligne:	https://doaj.org/article/77ff7ef076ce42c0bd7b814e4a482e9c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:77ff7ef076ce42c0bd7b814e4a482e9c
record_format	dspace
spelling	oai:doaj.org-article:77ff7ef076ce42c0bd7b814e4a482e9c2021-11-25T07:56:43ZInterleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?2639-802810.1097/CCE.0000000000000542https://doaj.org/article/77ff7ef076ce42c0bd7b814e4a482e9c2021-10-01T00:00:00Zhttp://journals.lww.com/10.1097/CCE.0000000000000542https://doaj.org/toc/2639-8028OBJECTIVES:. To examine whether interleukin-6 in critical coronavirus disease 2019 is higher in arterial than in central venous blood, as a sign of predominantly local pulmonal rather than systemic interleukin-6 production. DESIGN:. Prospective cohort pilot study with repeated weekly measurements of interleukin-6 in arterial and central venous blood. Respiratory function, assessed with Pao2/Fio2 ratio, was measured at the time of blood sampling. SETTING:. ICU at a university hospital. SUBJECTS:. Nine adult patients with critical coronavirus disease 2019, actively treated and receiving mechanical ventilation. MEASUREMENTS AND MAIN RESULTS:. No difference between arterial and central venous interleukin-6 was found. There was a significant negative relationship between interleukin-6 concentration and P/F ratio in both arterial (p = 0.04) and central venous (p = 0.03) blood. CONCLUSIONS:. The absence of an arteriovenous interleukin-6 difference implies that interleukin-6 in critical coronavirus disease 2019 is mainly produced outside the lungs as part of a systemic inflammatory response syndrome and act as a driver of local inflammation and damage in the lungs.Nikolai Ravn Aarskog, MDHans Christian Aass, PhDJan Cato Holter, MD, PhDMorten Rostrup, MD, PhDAleksander Rygh Holten, MD, PhDWolters KluwerarticleMedical emergencies. Critical care. Intensive care. First aidRC86-88.9ENCritical Care Explorations, Vol 3, Iss 10, p e0542 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medical emergencies. Critical care. Intensive care. First aid RC86-88.9
spellingShingle	Medical emergencies. Critical care. Intensive care. First aid RC86-88.9 Nikolai Ravn Aarskog, MD Hans Christian Aass, PhD Jan Cato Holter, MD, PhD Morten Rostrup, MD, PhD Aleksander Rygh Holten, MD, PhD Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?
description	OBJECTIVES:. To examine whether interleukin-6 in critical coronavirus disease 2019 is higher in arterial than in central venous blood, as a sign of predominantly local pulmonal rather than systemic interleukin-6 production. DESIGN:. Prospective cohort pilot study with repeated weekly measurements of interleukin-6 in arterial and central venous blood. Respiratory function, assessed with Pao2/Fio2 ratio, was measured at the time of blood sampling. SETTING:. ICU at a university hospital. SUBJECTS:. Nine adult patients with critical coronavirus disease 2019, actively treated and receiving mechanical ventilation. MEASUREMENTS AND MAIN RESULTS:. No difference between arterial and central venous interleukin-6 was found. There was a significant negative relationship between interleukin-6 concentration and P/F ratio in both arterial (p = 0.04) and central venous (p = 0.03) blood. CONCLUSIONS:. The absence of an arteriovenous interleukin-6 difference implies that interleukin-6 in critical coronavirus disease 2019 is mainly produced outside the lungs as part of a systemic inflammatory response syndrome and act as a driver of local inflammation and damage in the lungs.
format	article
author	Nikolai Ravn Aarskog, MD Hans Christian Aass, PhD Jan Cato Holter, MD, PhD Morten Rostrup, MD, PhD Aleksander Rygh Holten, MD, PhD
author_facet	Nikolai Ravn Aarskog, MD Hans Christian Aass, PhD Jan Cato Holter, MD, PhD Morten Rostrup, MD, PhD Aleksander Rygh Holten, MD, PhD
author_sort	Nikolai Ravn Aarskog, MD
title	Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?
title_short	Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?
title_full	Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?
title_fullStr	Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?
title_full_unstemmed	Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?
title_sort	interleukin-6 in critical coronavirus disease 2019, a driver of lung inflammation of systemic origin?
publisher	Wolters Kluwer
publishDate	2021
url	https://doaj.org/article/77ff7ef076ce42c0bd7b814e4a482e9c
work_keys_str_mv	AT nikolairavnaarskogmd interleukin6incriticalcoronavirusdisease2019adriveroflunginflammationofsystemicorigin AT hanschristianaassphd interleukin6incriticalcoronavirusdisease2019adriveroflunginflammationofsystemicorigin AT jancatoholtermdphd interleukin6incriticalcoronavirusdisease2019adriveroflunginflammationofsystemicorigin AT mortenrostrupmdphd interleukin6incriticalcoronavirusdisease2019adriveroflunginflammationofsystemicorigin AT aleksanderryghholtenmdphd interleukin6incriticalcoronavirusdisease2019adriveroflunginflammationofsystemicorigin
_version_	1718413627357134848

Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin?

Documents similaires